Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

摘要: Over the last 18 months, 3 immunotherapy combination regimens (ipilimumab + nivolumab, pembrolizumab axitinib, and axitinib avelumab) were approved by US Food Drug Administration for first-line treatment of metastatic renal cell carcinoma (mRCC), making selection optimal regimen very challenging. As April 2020, preferred options mRCC are ipilimumab based on improvement in overall survival progression-free compared to sunitinib, as observed pivotal phase III clinical trials. Because 2 drugs is typically more toxic than a monotherapy, careful attention must be given overlapping toxicities. The led grade ≥3 adverse events 75.8% patients (vs 70.6% sunitinib group), while less frequent nivolumab group group. Discontinuation rates due toxicity 10.7% (both drugs), 22% comparable with both studies (13.9% 12%, respectively). may have immune-modulating functions that provide benefit without additional nivolumab. In addition, this tyrosine kinase inhibitor immune checkpoint should faster response larger disease burden or symptomatic patients, which makes an excellent choice mRCC. These combinations proven tolerable, though long-term results still lacking. rapidly expanding, could potentially change paradigm, ultimate goal prolonging life eventually curing